Problem

Most people know their chronological age but lack a clinically actionable view of how quickly individual organs and physiological systems are aging. Generation Lab targets the gap between conventional disease testing, which often identifies problems after symptoms or abnormalities appear, and proactive health management: its stated goal is to detect accelerated aging and disease risk earlier, then show where intervention may matter most. The economic rationale is prevention: chronic disease imposes substantial healthcare and productivity costs, while consumers and longevity clinicians lack a reliable way to quantify whether expensive lifestyle, supplement, or clinical interventions are actually improving underlying health.

The killer use case is a healthy or health-conscious person who wants to prevent disease rather than react to it. By identifying which systems are aging fastest, SystemAge is intended to turn vague longevity advice into a measurable plan that can be followed and retested over time; the same capability gives longevity clinics a dashboard for guiding and evaluating interventions for patients, athletes, and other high-performance customers.

Product / Service

Generation Lab’s flagship product is SystemAge™, a direct-to-consumer and clinic-enabled biological-age diagnostic. The current SystemAge 2.1 release uses a needle-free blood collection device and analyzes more than 460 biomarkers across 21 organ systems, with female- and male-specific versions, rather than reducing aging to one overall age score. Customers can order a $499 test, collect a sample at home, receive a digital report in roughly three to four weeks, and use the results to understand system-specific biological age, risks, and personalized intervention priorities.

The service is designed as a measurement-and-action loop rather than a one-time lab result. Reports provide tailored recommendations, while professionals and the company’s digital tools can help users implement them; longitudinal views and repeat testing show whether a chosen intervention is changing the relevant systems. Generation Lab also distributes SystemAge through longevity physicians, wellness centers, and other provider clinics, giving clinicians a way to use the diagnostic alongside personalized health programs.

Market

Generation Lab competes in the emerging longevity-diagnostics and preventive-health market, at the intersection of epigenetic testing, biological-age measurement, precision wellness, and longevity medicine. Its closest named alternatives include TruDiagnostic, Tally Health, Function Health, and GlycanAge. TruDiagnostic and Tally Health are the most direct biological-age comparables, while Function Health is broader conventional biomarker testing and GlycanAge focuses more narrowly on inflammation. Generation Lab differentiates SystemAge around organ-by-organ aging clocks, a blood-based collection method, and intervention plans intended to be more actionable than a single aggregate age score.

The company is commercially launched rather than pre-revenue in the sense of being only a prototype: the test is offered for purchase and, as of June 2026, Generation Lab said SystemAge was deployed across more than 750 clinics in 18 countries. It reported more than 300 million human-aging data points, 99% accuracy across 1,605 test cases for SystemAge 2.1, and $11 million in seed funding that brought total funding to $15 million. Those adoption and financing figures indicate strong early traction, although the available research does not disclose revenue, paid-test volume, margins, or independent validation of the company’s performance claims.